Treatment of hypertension in chronic renal insufficiency

Internal Medicine

Volumn 39, Issue 10, 2000, Pages 773-777

  Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Ambulatory blood pressure; Angiotensin converting enzyme inhibitor; Benign nephrosclerosis; Calcium antagonist; Chronic glomemlonephritis; Self reported blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

AGE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HUMAN; HYPERTENSION; RACE; REVIEW; SEX DIFFERENCE;

EID: 0033774010     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.39.773     Document Type: Review

References (40)

1. Klahr S, Levey A, Beck GJ, et al The effects of dietary protein restirction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884, 1994.
2. Maschio G, Alberti D, Janin G, et al Effect of the angiotensin convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996.
3. Guidelines Subcommittee. 1999 World Health Organization-International Soceity of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17: 151-183, 1999.
4. The sixth report of the Joint National Committee on prevention, evaluation, detection, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157: 2413-2446, 1997 (published erratum appears in Arch Intern Med 158: 573, 1998).
5. Klahr S. Role of dietary protein and blood pressure in the progression of renal disease. Kidney Int 49: 1783-1786, 1996.
6. Ruggenenti P, Perna A, Zoccali C, et al and Gruppo Italiano dei Studi Epidemiologici in Nefrologia" (GISEN). Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patietns: Differences between women and men in relation ot the ACE gene polymorphism. J Am Soc Nephrol 11: 88-96, 2000.
7. Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progressin of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 27: 652-663, 1996.
8. Lazarus JM, Bourgoignie JJ, Buckalew JM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 29: 641-650, 1997.
9. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of progresion of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908-1919, 1997.
10. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 30: 428-435, 1997.
11. Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 7: 2616-2626, 1996 (published erratum appears in J Am Soc Nephrol 8: 493, 1997).
12. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123: 754-762, 1995.
13. Locatelli F, Carbarns IRI, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int Suppl 63: S-63-S-66, 1997.
14. Ruggenenti P, Perna A, Benini R, et al and Investigators of the GISEN Group. In chronic nephropathies prologned ACE inhibition can induce remission: Dynamics of time-dependent chagnes in GFR. Gruppo Italian Studi Epidemiologici in Nepfrologia. J Am Soc Nephrol 10: 997-1006, 1999.
15. The GISEN Group (Gruppo Italian di Studi Epidemiologici in Nefrologia). Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997.
16. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53: 1209-1216, 1998.
17. Ruggunenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G, and "Gruppo Italiano dei Studi Epidemiologici in Nefrologia" (GISEN): Renal function and requirement for dialysis in chronic nephropahty patients on long-term ramipril: REIN follow-up trial. Ramipril Efficacy in Nephropathy.Lancet 352: 1252-1256, 1998.
18. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
19. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986.
20. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29: 526-532, 1997.
21. Katafuchi R, Takebayashi S, Taguchi T. Hypertension-related aggravation of IgA nephropathy. Clin Nephrol 30: 261-269, 1988.
22. Bannister KM, Weaver A, Clarrkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression in IgA nephropathy. Contrib Neprhol 104: 389-397, 1995.
23. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23: 247-254, 1994.
24. Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associates with preservation of renal funciton in hypertensive patients with IgA nephropathy: a 3 year observation. Clin Nephrol 2000 (in press).
25. Mountokalakis TD. The renal consequences of arterial hypertension. Kidney Int 51: 1639-1653, 1997.
26. Saruta T, Kumagai H. The sympathetic nervous system in hypertension and renal disease. Curr Opin in Nephrol Hypertens 5: 72-79, 1996.
27. Timio M, Venanzi S, Lolli S, et al. "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 43: 383-387, 1995.
28. Timio M, Lolli S, Verdura C, Monarca C, Merante F, Guerrini E. Circadian blood pressure changes in patients with chronic renal insufficiency: A prospective study. Ren Fail 15: 231-237, 1993.
29. Portaluppi F, Montanari L, Massari M, Di Chiara V, Capanna M. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens 4: 20-26, 1991.
30. Perloff D, Sokolow M, Cowan RM, Juster RP. Prognostic value of ambulatory blood pressure measurements: further analyses. J Hypertens Suppl 7: S3-S10, 1989.
31. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 5: 93-98, 1987.
32. Baumgart P, Walger P, Gemen S, von Eiff M, Raidt H, Rahn KH. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 57: 293-298, 1991.
33. Cottone S, Panepinto N, Vadala A, et al. Sympathetic overactivity and 24-hour blood pressure pattern in hypertensives with chronic renal failure. Ren Fail 17: 751-758, 1995.
34. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340: 1321-1328, 1999.
35. Thijs L, Staessen JA, Celis H, et al. Reference values for self-recorded blood pressure: A meta-analysis of summary data. Arch Intern Med 158: 481-488, 1998.
36. Rave K, Bender R, Heise T, Sawicki PT. Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy. J Hypertens 17: 597-601, 1999.
37. de Gaudemaris R, Chau NP, Mallion J-M, and the Group de la Mesure French Soiety of Hypertension: Home blood pressure: variability, comparison with office readings and proposal for reference values. J Hypertens 12: 831-838, 1994.
38. Fogo A, Breyer JA, Smith MC, et al and AASK Pilot Study Investigators: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. Kidney Int 51: 244-252, 1997.
39. Toto RD, Mitchell HC, Smith RD, Lee HC, Mclntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48: 851-859, 1995.
40. Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 29: 720-726, 1997.